DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C

Clinical trials for DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C explained in plain language.

Never miss a new study

Get alerted when new DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C trials appear

Sign up with your email to follow new studies for DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Could your blood type change your cancer treatment?

Disease control Not yet recruiting

This study is testing whether personalized dosing guidelines for people with a specific blood type (Duffy null) can help them better tolerate standard cancer treatments. Researchers will enroll 90 people with multiple myeloma or triple-negative breast cancer to see if these tailo…

Matched conditions: DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C

Phase: PHASE1 • Sponsor: Andrew Hantel, MD • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C

Get alerted when new DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C trials appear

Could your blood type change your cancer treatment?